CG Oncology (CGON) Expected to Announce Quarterly Earnings on Friday

CG Oncology (NASDAQ:CGON) is anticipated to announce its Q4 2025 results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. On average, analysts expect CG Oncology to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CG Oncology Trading Up 2.2%

Shares of NASDAQ:CGON opened at $65.86 on Friday. CG Oncology has a 12 month low of $14.80 and a 12 month high of $69.35. The company has a market capitalization of $5.56 billion, a price-to-earnings ratio of -31.82 and a beta of 1.18. The firm’s 50-day moving average is $56.66 and its 200 day moving average is $45.68.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 1,964 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $63.50, for a total value of $124,714.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Picton Mahoney Asset Management bought a new stake in CG Oncology during the 4th quarter valued at $118,000. Tower Research Capital LLC TRC grew its position in shares of CG Oncology by 159.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock worth $182,000 after buying an additional 4,288 shares in the last quarter. Sei Investments Co. purchased a new position in shares of CG Oncology during the second quarter valued at $209,000. Verition Fund Management LLC purchased a new position in shares of CG Oncology during the third quarter valued at $221,000. Finally, Man Group plc bought a new stake in shares of CG Oncology in the second quarter valued at about $224,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CGON has been the subject of several recent analyst reports. Royal Bank Of Canada boosted their target price on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Morgan Stanley set a $93.00 price target on CG Oncology in a research note on Friday, January 9th. The Goldman Sachs Group restated a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Wedbush initiated coverage on CG Oncology in a research report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price objective on the stock. Finally, Piper Sandler increased their target price on CG Oncology from $55.00 to $70.00 and gave the stock an “overweight” rating in a research note on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and an average price target of $69.00.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.